Paradigm Biopharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Paradigm Biopharmaceuticals'in kazançlarının artacağı tahmin edilmektedir. EPS'nin büyümesi yıllık 56.9% oranında azalması beklenmektedir.

Anahtar bilgiler

8.8%

Kazanç büyüme oranı

56.9%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.0%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	08 May 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:PBIG.F - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	N/A	-59	-66	-66	N/A
3/31/2024	0	-64	-72	-72	N/A
12/31/2023	0	-69	-78	-78	N/A
9/30/2023	0	-60	-62	-62	N/A
6/30/2023	N/A	-52	-45	-45	N/A
3/31/2023	0	-48	-39	-39	N/A
12/31/2022	0	-44	-33	-33	N/A
9/30/2022	0	-42	-33	-33	N/A
6/30/2022	0	-39	-32	-32	N/A
3/31/2022	0	-40	-32	-32	N/A
12/31/2021	0	-41	-32	-32	N/A
9/30/2021	0	-37	-34	-34	N/A
6/30/2021	0	-34	-35	-35	N/A
3/31/2021	0	-31	-29	-29	N/A
12/31/2020	-1	-28	-24	-23	N/A
9/30/2020	0	-20	-17	-17	N/A
6/30/2020	N/A	-12	-10	-10	N/A
3/31/2020	2	-14	-10	-10	N/A
12/31/2019	4	-16	-10	-10	N/A
9/30/2019	3	-16	-8	-8	N/A
6/30/2019	3	-16	-6	-6	N/A
3/31/2019	3	-11	-7	-7	N/A
12/31/2018	3	-7	-7	-7	N/A
9/30/2018	3	-7	-6	-6	N/A
6/30/2018	3	-6	-6	-6	N/A
3/31/2018	2	-6	N/A	-4	N/A
12/31/2017	2	-5	N/A	-3	N/A
9/30/2017	2	-5	N/A	-4	N/A
6/30/2017	2	-4	N/A	-4	N/A
3/31/2017	2	-4	N/A	-5	N/A
12/31/2016	1	-4	N/A	-6	N/A
9/30/2016	1	-4	N/A	-5	N/A
6/30/2016	1	-3	N/A	-4	N/A
3/31/2016	1	-3	N/A	-3	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-2	N/A	-1	N/A
6/30/2015	N/A	-2	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PBIG.F önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: PBIG.F önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: PBIG.F önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: PBIG.F şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: PBIG.F şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PBIG.F 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Paradigm Biopharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin